Stocksigma LogoStocksigma Logo

Symbiotec Pharmalab Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Million)

■ Revenue: 2,182 (+7.4% YoY | -11.1% QoQ) ■ EBITDA: 452 (-22.0% YoY | -27.2% QoQ) ■ EBITDA Margin (%): 20.7 (-781 bps YoY | -460 bps QoQ) ■ PAT: 141

Symbiotec Pharmalab Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Million)

Symbiotec Pharmalab Ltd · Outcome · 22 Sept 2026, 12:02 am

Symbiotec Pharmalab Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Million) ■ Revenue: 2,182 (+7.4% YoY | -11.1% QoQ) ■ EBITDA: 452 (-22.0% YoY | -27.2% QoQ) ■ EBITDA Margin (%): 20.7 (-781 bps YoY | -460 bps QoQ) ■ PAT: 141 (-53.0% YoY | -48.9% QoQ) ■ EPS (INR): 2.24 (-58.1% YoY | -52.9% QoQ)

Original exchange filing (PDF)

More announcements from Symbiotec Pharmalab Ltd

All Symbiotec Pharmalab Ltd announcements